Clinical Trial Search

Primary: Multidimensional Assessment of Fatigue (MAF) Questionnaire: Global Fatigue Score After 4 Weeks of Treatment on Each Drug/Dose Combination. — 18.5; 18.0; 21.0; 20.3 units…

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52 — -1.35; -0.98 % HbA1c — p=<0.001

Primary: Number of Participants With Adverse Events (AEs) — 3; 3; 3; 13 Participants

Primary: Patient-Rated Wrist Evaluation (PRWE) — 30.5; 15.2 units on a scale

Primary: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate — 0.099 probability of events at 30 days

Primary: Frequency of Epistaxis — 7.0; 8.0; 7.5; 8.0 Bleeding episodes per week — p=0.97

Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scale — 3.3; 3.0; 2.9 units on scale

Primary: Cue Craving Rating — 9.36; 7.92 scores on a scale

Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541 — 128000; 145000; 135000 picomoles times hours per liter

Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of LY2216684 — 582; 746 nanogram*hours per milliliter (ng*h/mL)

Primary: Time to Progression — 3.12; 1.64 months

Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541 — 85200; 67200; 64300; 66600 picomole*hours/liter (pmol*h/L)

Primary: Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of S-Warfarin — 22200; 20800 nanogram*hour per milliliter (ng*hr/mL)

Primary: First Attempt's Success Rate of Insertion — 73.3; 86.6 percentage of participants

Primary: Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population — 0.15; 0.38; 0.41; 0.64 Percetage of subjects